Virax Biolabs Group Limited (VRAX) Adds Three China Distributors for ImmuneSelect

Virax Biolabs (VRAX) signed agreements with AmyJet, Jiangsu Real-Gen, and Zhixi to distribute its ImmuneSelect RUO immune profiling products in China. This marks an early commercial expansion for Virax's RUO portfolio in the region.

Original reporting
Published Oct 29, 2026, 11:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 11:37 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Virax Biolabs Group Limited (VRAX) Adds Three China Distributors for ImmuneSelect — source image
Decision brief

The 30-second read

$VRAXNeutralLow
01

Why it matters

The distribution deals are a modest corporate development that could incrementally improve top‑line if successful.

02

Market read

A micro‑cap biotech announces new China distribution agreements; limited immediate market impact.

03

What to watch

Potential regulatory hurdles for RUO products in China could delay or limit sales.

Relevance 5/10Novelty 5/10Timing: today

Background

Virax Biolabs is a small biotech focused on immune profiling reagents; expanding its China footprint.

Company-level read

Ticker impact

$VRAXNeutralMedium confidence
Context

Virax Biolabs signed non‑exclusive distribution agreements with three Chinese partners to sell its ImmuneSelect RUO products.

Expected impact

modest upside pressure as investors price in potential future revenue from China distribution

Evidence & confidence

First disclosure of the agreements; no financial terms disclosed, so market reaction is likely muted.

Market effects

May signal growing interest in RUO immunoprofiling tools within Chinese biotech market.

Limited to Chinese distribution channel; unlikely to affect broader regional indices.

Minimal; primarily a micro‑cap specific development.

Counterpoint

Without disclosed order volumes, the agreements may not translate into meaningful revenue, keeping the stock flat.

Key entities

  • Virax Biolabs Group Limited

    US‑listed biotech (NASDAQ: VRAX) developing immune profiling products.

  • AmyJet

    Chinese distributor partner.

  • Jiangsu Real-Gen

    Chinese distributor partner.

  • Zhixi

    Chinese distributor partner.

Related articles

$VRAXMed

Top Biotech Gainers: VRAX Jumps 100% After Fosun Deal, FBRX Soars On Vitiligo Data, TRAX On Watch

Biotech stocks rose on company-specific catalysts. Virax Biolabs (VRAX) jumped over 100% after signing an exclusive multi-country supply agreement with Fosun Diagnostics for ImmuneSelect. Forte Biosciences (FBRX) gained about 78% on positive Phase 1b vitiligo data for FB102. First Tracks (TRAX) rose ~56% without news. TransCode (RNAZ) and Connect Biopharma (CNTB) also climbed; Sanuwave (SNWV) fell guidance and expects Q2 revenue of $8.5m to $9.5m.

$VRAXMed

Why Did Virax Biolabs Stock Triple In One Session? - Virax Biolabs Group (NASDAQ:VRAX)

Virax Biolabs Group (NASDAQ:VRAX) shares surged 228.13% to $10.43 after the company announced an exclusive supply agreement with Fosun Diagnostics covering six Southeast Asian markets. The deal provides immediate product supply via purchase orders and targets near-term revenue, including tuberculosis-related RUO research in Thailand. VRAX also completed a 1-for-25 share consolidation.

$VRAXMed

Virax Signs Multi-Country Commercial Supply Agreement With Fosun Diagnostics; Stock Skyrockets

Virax Biolabs Group (VRAX) said its subsidiary Virax Biolabs (UK) signed an exclusive multi-country commercial supply agreement with Fosun Diagnostics for its ImmuneSelect immune profiling products. The deal covers Thailand, Vietnam, Indonesia, the Philippines, Singapore, and Malaysia, with supply via purchase orders. Fosun Diagnostics is part of Fosun Medtech, and VRAX shares rose on the news.

$VRAXMed

Virax Biolabs stock surges 100% on Fosun supply deal By Investing.com

Virax Biolabs Group (NASDAQ:VRAX) shares jumped 100% after it signed an exclusive multi-country supply agreement with Fosun Diagnostics for its ImmuneSelect immune profiling products. The deal covers six ASEAN markets and enables immediate supply via purchase orders, with initial focus on tuberculosis research in Thailand. ImmuneSelect is research-use-only, separate from Virax’s in-development diagnostic platform.